Company Description
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally.
Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing.
MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 1999 |
| IPO Date | Jul 30, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Maher Masoud |
Contact Details
Address: 9713 Key West Avenue, Suite 400 Rockville, Maryland 20850 United States | |
| Phone | 301-517-5556 |
| Website | maxcyte.com |
Stock Details
| Ticker Symbol | MXCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 0001287098 |
| CUSIP Number | 57777K106 |
| ISIN Number | US57777K1060 |
| Employer ID | 52-2210438 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maher Masoud | President, Chief Executive Officer, Secretary and Director |
| Douglas Arthur Doerfler | Founder |
| Douglas J. Swirsky CFA, CPA | Chief Financial Officer |
| Jay Gelfman | Senior Vice President of Operations |
| Ronald Evan Holtz CPA, Ph.D. | Executive Vice President of Administration |
| Sean Menarguez | Director of Investor Relations |
| David Sandoval | Senior Vice President and General Counsel |
| Thomas Michael Ross | Executive Vice President of Global Sales |
| Jack Horgan | Vice President of Corporate Development |
| Jill Mayer | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 12, 2024 | 10-K | Annual Report |
| Mar 12, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 144 | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 1, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2024 | 8-K | Current Report |